Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT)
This study has been completed.
Information provided by (Responsible Party):
First received: October 22, 2008
Last updated: April 21, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 2015|
|Primary Completion Date:||August 2006 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.